Abstract:Background: Metastatic disease lacks effective treatments and remains the primary cause of mortality from epithelial cancers, especially breast cancer. The metastatic cascade involves cancer cell migration and invasion and modulation of the tumor microenvironment (TME). A viable anti-metastasis strategy is to simultaneously target the migration of cancer cells and the tumor-infiltrating immunosuppressive inflammatory cells such as activated macrophages, neutrophils, and myeloid-derived suppressor cells (MDSC). The Rho GTPases Rac and Cdc42 are ideal molecular targets that regulate both cancer cell and immune cell migration, as well as their crosstalk signaling at the TME. Therefore, we tested the hypothesis that Rac and Cdc42 inhibitors target immunosuppressive immune cells, in addition to cancer cells. Our published data demonstrate that the Vav/Rac inhibitor EHop-016 and the Rac/Cdc42 guanine nucleotide association inhibitor MBQ-167 reduce mammary tumor growth and prevent breast cancer metastasis from pre-clinical mouse models without toxic effects. Methods: The potential of Rac/Cdc42 inhibitors EHop-016 and MBQ-167 to target macrophages was tested in human and mouse macrophage cell lines via activity assays, MTT assays, wound healing, ELISA assays, and phagocytosis assays. Immunofluorescence, immunohistochemistry, and flow cytometry were used to identify myeloid cell subsets from tumors and spleens of mice following EHop-016 or MBQ-167 treatment. Results: EHop-016 and MBQ-167 inhibited Rac and Cdc42 activation, actin cytoskeletal extensions, migration, and phagocytosis without affecting macrophage cell viability. Rac/Cdc42 inhibitors also reduced tumor- infiltrating macrophages and neutrophils in tumors of mice treated with EHop-016, and macrophages and MDSCs from spleens and tumors of mice with breast cancer, including activated macrophages and monocytes, following MBQ-167 treatment. Mice with breast tumors treated with EHop-016 significantly decreased the proinflammatory cytokine Interleukin-6 (IL-6) from plasma and the TME. This was confirmed from splenocytes treated with lipopolysaccharide (LPS) where EHop-016 or MBQ-167 reduced IL-6 secretion in response to LPS. Conclusion: Rac/Cdc42 inhibition induces an antitumor environment via inhibition of both metastatic cancer cells and immunosuppressive myeloid cells in the TME.

Targeting Rac and Cdc42 GEFs in Metastatic Cancer

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Rac1: A Regulator of Cell Migration and A Potential Target for Cancer Therapy

Targeting Rho GTPase Signaling Networks in Cancer

Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models

Epigenetically Upregulated GEFT-derived Invasion and Metastasis of Rhabdomyosarcoma Via Epithelial Mesenchymal Transition Promoted by the Rac1/Cdc42-PAK Signalling Pathway.

Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.

Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA As New Treatment Candidates

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma

The role of RhoC in malignant tumor invasion, metastasis and targeted therapy.

Abstract 1881: Screening of Rac1 and Cdc42 inhibitors as anti-metastatic compounds

The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review

The P-Rex1/Rac signaling pathway as a point of convergence for HER/ErbB receptor and GPCR responses

Ran GTPase: A Key Player in Tumor Progression and Metastasis

Rho GTPases: Regulation and roles in cancer cell biology

Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers

Mechanisms of Rho GTPases in regulating tumor proliferation, migration and invasion

Advances in the Development of Rho GTPase Inhibitors

New Mechanisms Underlying Oncogenesis in Dbl Family Rho Guanine Nucleotide Exchange Factors

Rho GTPases in cancer: friend or foe?